← Back to Drugs A–Z

Mephedrone

Nicknames: mcat, mkat, 4-mmc, drone, miaow, bubbles, meow meow, meph, bounce
Last reviewed: October 2026

Pharmacology

Mephedrone acts as a potent monoamine releasing agent alongside inhibiting their reuptake, in a similar way to MDMA and amphetamines. This means that mephedrone causes dopamine, serotonin and noradrenaline levels to increase rapidly at the synapse (gap) between nerve cells. Mephedrone’s preference for serotonin over dopamine is likely responsible for its MDMA-like effects. However, mephedrone has a weaker affinity for the serotonin transporter (SERT) than MDMA, explaining why its entactogenic effects are less prominent. This more balanced profile of monoamines gives mephedrone its characteristic position as a middle ground between MDMA and cocaine.

Mephedrone is rapidly absorbed, reaching peak concentrations in the blood 30–60 min after oral or intranasal administration. It has a relatively short duration of effects, with a half life of around 2 hours. Mephedrone is broken down primarily by the CYP2D6 enzyme in the liver. As such, taking mephedrone with CYP2D6 inhibitors such as ritonavir is likely to pose significant health risks.

Due to its serotonergic activity, mephedrone taken in combination with MAOIs such as phenelzine carries an increased risk of overdose and serotonin syndrome. It is likely that, like MDMA, SSRIs and SNRIs may blunt the subjective effects of mephedrone.

Keep This Information Independent

Release is a registered charity. We rely on your support to provide expert, non-judgmental legal and harm reduction guidance to thousands of people every year.

Donate to Release